Search
Acumen Pharmaceuticals Inc
ABOSAdd to Watchlist
2.270USD
+0.290+14.65%
Close 10-26 16:00（ET）
164.17MMarket Cap
LossP/E TTM
After-hours 18:38 (ET)2.340USD+0.050+2.18%
After-hours 18:38 (ET)Acumen Pharmaceuticals Inc (ABOS) Stock Price Target & Forecast
Analyst Rating
Based on 6 analysts giving stock ratings to Acumen Pharmaceuticals Inc in the past month.
Strong Buy
4 Strong Buy
2 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
7.600USD+349.70%
ABOS Analyst Recommendation Trends
In the current month, ABOS has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ABOS average Analyst price target in the last month is 7.600.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
4
4
4
4
4
4
4
4
2
2
2
2
2
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
6
6
6
6
6
6
6
ABOS Analyst Rating for Peer Comparison
Updated: Oct 20, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
18
0
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
Biontech SE
BNTX
4
12
8
0
0
24
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
Cytokinetics Inc
CYTK
5
16
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Financial Forecasting
Based on analysts' estimates, ABOS EPS is projected to reach -0.381 in FY2026Q3, following reported EPS of -0.453 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.45
-0.40
-0.37
-0.38
-0.36
Actual
-0.41
-0.33
-0.45
--
--
Surprise
+8.43%
+18.55%
-23.32%
--
--
FAQs
What is Acumen Pharmaceuticals Inc's price target?
Analysts forecast that Acumen Pharmaceuticals Inc's price target is USD 7.60, with the highest forecast at USD 10.00 and the lowest forecast at USD 5.00.
How have Acumen Pharmaceuticals IncABOS's recent earnings per share performed?
The market expectation was USD -0.45, while Acumen Pharmaceuticals IncABOS's earnings per share (EPS) for the previous quarter was USD -0.33. EPS for the next quarter is expected at USD -0.38.
What is the analyst rating for Acumen Pharmaceuticals Inc?
Based on the ratings of Acumen Pharmaceuticals Inc's stock from 6 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.